Please login to the form below

Not currently logged in
Email:
Password:

DCVax-L

This page shows the latest DCVax-L news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo set for early access in UK

BMS' Opdivo set for early access in UK

Until now, the only PIM granted under the scheme was for Northwest Biotherapeutics' cell-based therapy DCVax-L for a form of brain cancer known as malignant glioma.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics